TNFα, a cytokine associated with tumor killing, was induced from baseline levels in 32% of patients treated with GRID therapy and was correlated with improved clinical response, whereas TGFβ, a cytokine putatively associated with tumor burden, decreased in 50% with no correlation to response rates [60]. This evidence concerns the gene TGFB1 and neoplasm.